ATE182902T1 - Der hepatische wachstumsfaktor (hgf) ist das met- proto-onkogen - Google Patents

Der hepatische wachstumsfaktor (hgf) ist das met- proto-onkogen

Info

Publication number
ATE182902T1
ATE182902T1 AT92905178T AT92905178T ATE182902T1 AT E182902 T1 ATE182902 T1 AT E182902T1 AT 92905178 T AT92905178 T AT 92905178T AT 92905178 T AT92905178 T AT 92905178T AT E182902 T1 ATE182902 T1 AT E182902T1
Authority
AT
Austria
Prior art keywords
hgf
growth factor
proto
met
oncogen
Prior art date
Application number
AT92905178T
Other languages
English (en)
Inventor
Donald P Bottaro
Jeffrey S Rubin
Donna Faletto
Andrew M-L Chan
Woude George Vande
Stuart A Aaronson
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE182902T1 publication Critical patent/ATE182902T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT92905178T 1991-01-18 1992-01-15 Der hepatische wachstumsfaktor (hgf) ist das met- proto-onkogen ATE182902T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/642,971 US5648273A (en) 1989-12-27 1991-01-18 Hepatic growth factor receptor is the MET proto-oncogene

Publications (1)

Publication Number Publication Date
ATE182902T1 true ATE182902T1 (de) 1999-08-15

Family

ID=24578815

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92905178T ATE182902T1 (de) 1991-01-18 1992-01-15 Der hepatische wachstumsfaktor (hgf) ist das met- proto-onkogen

Country Status (11)

Country Link
US (1) US5648273A (de)
EP (1) EP0567585B1 (de)
JP (2) JP2598362B2 (de)
AT (1) ATE182902T1 (de)
AU (1) AU652031B2 (de)
CA (2) CA2099865C (de)
DE (1) DE69229720T2 (de)
DK (1) DK0567585T3 (de)
ES (1) ES2136082T3 (de)
GR (1) GR3031381T3 (de)
WO (1) WO1992013097A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
CA2102595C (en) * 1991-05-10 2003-01-14 Paolo Comoglio Truncated forms of the hepatocyte growth factor (hgf) receptor
ATE160585T1 (de) * 1992-09-18 1997-12-15 Us Gov Health & Human Serv Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5855918A (en) * 1995-09-12 1999-01-05 Genentech, Inc. Cystic fibrosis therapy
US5866329A (en) * 1995-09-27 1999-02-02 Demetriou; Achilles A. Method and probe for detection of gene associated with liver neoplastic disease
WO1997012629A1 (en) * 1995-10-05 1997-04-10 Genentech, Inc. Improved angiogenesis using hepatocyte growth factor
AU7389496A (en) * 1995-10-05 1997-04-28 Genentech Inc. Methods and compositions for treating vascular stenosis
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ES2274567T3 (es) * 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.
EP1320384B1 (de) * 2000-08-28 2007-10-10 Damavand Wound AB Die synergistischen wirkungen von hgf und antibakterieller behandlung
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
DK1687636T3 (da) * 2003-09-29 2009-05-11 Peas Inst Ab Hurtig bestemmelse af forskellige former for hepatocytvækstfaktor (HGF) i legemsvæsker
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
EP1838736B1 (de) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto-bindende moleküle
EP1863519B1 (de) 2005-03-31 2013-09-25 The General Hospital Corporation Modulation von hgf/hgfr-aktivität zur behandlung von lymphödem
CN101193910A (zh) 2005-04-15 2008-06-04 健泰科生物技术公司 HGFβ链变体
EP1952826A4 (de) * 2005-10-24 2011-05-18 Fujifilm Ri Pharma Co Ltd Diagnostisches mittel und therapeutisches mittel für erkrankungen im zusammenhang mit dem hepatozyten-wachstumsfaktor-rezeptor
EP1957541A2 (de) * 2005-11-21 2008-08-20 Laboratoires Serono SA Zusammensetzungen und verfahren zur herstellung von antigenbindenden hybridmolekülen und anwendungen davon
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9676849B2 (en) 2012-01-10 2017-06-13 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
US11077132B2 (en) 2015-02-04 2021-08-03 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030565A (en) * 1983-08-17 1991-07-09 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands

Also Published As

Publication number Publication date
CA2176620C (en) 2001-04-24
CA2099865A1 (en) 1992-07-19
DE69229720D1 (de) 1999-09-09
JPH06505968A (ja) 1994-07-07
JP3387745B2 (ja) 2003-03-17
EP0567585A4 (de) 1994-08-03
DE69229720T2 (de) 2000-04-27
US5648273A (en) 1997-07-15
CA2099865C (en) 1997-11-25
AU1273892A (en) 1992-08-27
AU652031B2 (en) 1994-08-11
EP0567585A1 (de) 1993-11-03
EP0567585B1 (de) 1999-08-04
DK0567585T3 (da) 1999-12-13
ES2136082T3 (es) 1999-11-16
JP2598362B2 (ja) 1997-04-09
GR3031381T3 (en) 2000-01-31
CA2176620A1 (en) 1992-07-19
JPH09127107A (ja) 1997-05-16
WO1992013097A1 (en) 1992-08-06

Similar Documents

Publication Publication Date Title
ATE182902T1 (de) Der hepatische wachstumsfaktor (hgf) ist das met- proto-onkogen
FI872756A0 (fi) Med laserstraolning fungerande terapeutisk anordning.
NL930112I2 (nl) Benzazepine-2-onen, werkwijzen ter bereiding daarvan, farmaceutische preparaten die deze verbindingen bevatten, alsmede de verbindingen voor de therapeutische toepassing.
DE69331510D1 (de) TNF-Liganden
NO870560L (no) Nytt farmasoeytisk preparat.
NO913625D0 (no) Fremgangsmaate for fremstilling av nye carbocykliske adenosinanaloger.
NO163435C (no) Pasientstol for roentgenundersoekelser.
DE69330494D1 (de) Radioaktiv markierte somatostatin
FR2613937B1 (fr) Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer
NO901423L (no) Fremgangsmaate for fremstilling av selektive adenosinreseptormidler.
SE8204873D0 (sv) Farmaceutiska preparat, innefattande humant insulin och human c-peptid
NO884533D0 (no) Fremgangsmaate for fremstilling av derivater av 2,2-dimetylkromen.
Hungund et al. A sensitive gas chromatographic method for the determination of methylphenidate (Ritalin) and its major metabolite alpha-phenyl-2-piperidine acetic acid (ritalinic acid) in human plasma using nitrogen-phosphorous detector
IT7820912A0 (it) Procedimento per la preparazione di derivati di cefalosporina, e composti cosi' preparati.
IT1285158B1 (it) Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il
NO873727L (no) Fremgangsmaate for fremstilling av benzoksazoninforbindelser med terapeutisk aktivitet.
IT8249771A0 (it) Derivati di cicloesanone aventi attivita' diserbante, e procedimento per la loro preparazione
OA06525A (fr) Préparation de dérivés hydroxylés de l'isopropylamino-pyrimidine (séquence réduction oxygène).
FI884461A7 (fi) Menetelmä trans-1,1,2-trifenyylibut-1-eenijohdannaisten valmistamiseksi
ATA279787A (de) Verwendung eines oestradiolderivates zur herstellung eines pharmazeutischen praeparates zur unterdrueckung der immunreaktion
NO900969D0 (no) Fremgangsmaate for fremstilling av anilin-derivat.
NL7808124A (nl) Nieuwe dibenzo( d,g)( 1,3,6)dioxazocine derivaten, werkwijze voor het bereiden daarvan alsmede voornoemde derivaten bevattende farmaceutische preparaten.
IT1060117B (it) 4 alchil diossi alchilen 5 benzil pirimidine, procedimento per la loro preparazione e preparati medicinali
DE3679255D1 (de) Behandlung chronischer entzuendungskrankheiten.
DK229089A (da) Peptid-laegemiddelpraeparater indeholdende alfa-aminoborsyrederivater til indgift via slimhinden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time